DakoCytomation to market LightUp's assays:
This article was originally published in Clinica
LightUp Technologies has granted Danish company, DakoCytomation co-exclusive rights to market and sell its line of ReSSQ infectious disease diagnostic products in Europe. The two companies will also collaborate on developing other products based on LightUp's proprietary assay technology. Huddinge, Sweden-based LightUp says its range of infectious disease diagnostics, based on nucleic acid detection, enables simpler and more accurate identification and quantification of disease generating organisms. The LightUp probe, inherent to the system, is designed to work with real-time PCR and can have several applications, including gene mapping and disease diagnostics.
You may also be interested in...
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.